genOway

Equities

ALGEN

FR0004053510

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:49:45 2024-04-24 am EDT			5-day change	1st Jan Change
3.96 ^EUR	+0.51%		+0.51%	-13.91%

2023	GenOway: sharp rise, broker initiates buy recommendation	CF
2023	GENOWAY : Euroland initiates buy coverage	CF

Genoway S.A. Reports Earnings Results for the Half Year Ended June 30, 2020

September 17, 2020 at 12:02 pm EDT

genOway S.A. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced total revenue was EUR 7.302 million. Operating loss was EUR 826,440. Net loss was EUR 958,632.

Latest news about genOway

GenOway: sharp rise, broker initiates buy recommendation	Nov. 22	CF
GENOWAY : Euroland initiates buy coverage	Nov. 22	CF
GenOway: profitability target achieved ahead of schedule	23-09-22	CF
GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Global markets live: Exxon Mobil, Apple, KKR, Amazon, Tesla...	23-04-11
GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
Sigma-Aldrich and genOway Expand Their CRISPR/CAS9 Strategic Alliance	22-09-08	CI
GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
GenOway Grants the Leading UK Academic Research Funder A Non-Exclusive License for CRISPR/Cas9 Technology	22-01-25	CI
Global markets live: Michelin, Facebook, UBS, Tesla, Volvo...	21-10-26
Genoway Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-27	CI
GenOway Société anonyme announced that it has received €5.6 million in funding from NextStage AM	21-05-26	CI
GenOway Société anonyme announced that it expects to receive €5 million in funding from NextStage AM	21-05-05	CI
Genoway Soci?T? Anonyme Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Genoway S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-17	CI
GenOway S.A. announced that it has received €1.7 million in funding from Eximium SAS, Dassault Développement and other investors	20-01-27	CI
GenOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Partnership to All Animal Cell Models	20-01-07	CI
Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models	18-12-10	CI
GenOway S.A. acquired AXENIS S.A.S from Institut Pasteur de Lille.	18-09-24	CI
GenOway Société Anonyme agreed to acquire AXENIS S.A.S from Institut Pasteur de Lille for €0.19 million.	18-09-03	CI

Chart genOway

Duration

Period

More charts

Company Profile

Sector

Biotechnology & Medical Research

Calendar

2024-06-27 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOWAY	-13.91%	37.99M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research